{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T01:00:49Z","timestamp":1779066049372,"version":"3.51.4"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Breast cancer is a common malignant tumor in women, with a highest incidence and mortality among all of the female malignant tumors. Notably, targeted therapy has achieved impressive success in the treatment of breast cancer. As one class of the anti-tumor targeted therapeutics, Cyclin-Dependent Kinases 4\/6CDK4\/6inhibitors have shown good clinical activity in treating breast cancer. Nevertheless, despite the promising clinical outcomes, intrinsic or acquired resistance to CDK4\/6 inhibitors has limited the benefits of this novel target therapy. In the present review, we provide an overview of the currently known molecular mechanisms of resistance to CDK4\/6 inhibitors, and discuss the potential strategies to overcoming drug resistance improving the outcomes for breast cancer patients treated with CDK4\/6 inhibitors.<\/jats:p>","DOI":"10.3389\/fonc.2021.651541","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T06:53:23Z","timestamp":1622012003000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Breast Cancer Resistance to Cyclin-Dependent Kinases 4\/6 Inhibitors: Intricacy of the Molecular Mechanisms"],"prefix":"10.3389","volume":"11","author":[{"given":"Bin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianlin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaixin","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.294.5542.502","article-title":"NOBEL PRIZE IN PHYSIOLOGY OR MEDICINE: Cycling Toward Stockholm","volume":"294","author":"Balter","year":"2001","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000484167","article-title":"Mechanisms of Resistance to CDK4\/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response","volume":"12","author":"Guarducci","year":"2017","journal-title":"Breast Care (Basel Switzerland)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(14)71159-3","article-title":"The Cyclin-Dependent Kinase 4\/6 Inhibitor Palbociclib in Combination with Letrozole Versus Letrozole Alone as First-Line Treatment of Oestrogen Receptor-Positive, HER2-Negative, Advanced Breast Cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S137783","article-title":"Abemaciclib: A CDK4\/6 Inhibitor for the Treatment of HR+\/HER2- Advanced Breast Cancer","volume":"12","author":"Corona","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30165-3","article-title":"Cyclin-Dependent Kinase 4 and 6 Inhibitors for Hormone Receptor-Positive Breast Cancer: Past, Present, and Future","volume":"395","author":"Spring","year":"2020","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0019","article-title":"Palbociclib with Letrozole in Postmenopausal Women with ER+\/HER2\u2013 Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial","volume":"24","author":"Di\u00e9ras","year":"2019","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/14656566.2018.1429407","article-title":"Clinical Efficacy of Ribociclib as a First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"19","author":"Duso","year":"2018","journal-title":"Expert Opin Pharmacotherapy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 Final PFS: A Randomized Study of Abemaciclib as Initial Therapy For Advanced Breast Cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209615","article-title":"RB and Cell Cycle Progression","volume":"38","author":"C","year":"2006","journal-title":"Oncogene"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15916","DOI":"10.1038\/ncomms15916","article-title":"CDK4\/6 and Autophagy Inhibitors Synergistically Induce Senescence in Rb Positive Cytoplasmic Cyclin E Negative Cancers","volume":"8","author":"Vijayaraghavan","year":"2017","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4161\/cc.21195","article-title":"Therapeutic Response to CDK4\/6 Inhibition in Breast Cancer Defined by Ex Vivo Analyses of Human Tumors","volume":"14","author":"Jeffry","year":"2012","journal-title":"Cell Cycle (Georgetown Tex)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4161\/cc.21195","article-title":"Therapeutic Response to CDK4\/6 Inhibition in Breast Cancer Defined by Ex Vivo Analyses of Human Tumors","volume":"11","author":"Dean","year":"2012","journal-title":"Cell Cycle (Georgetown Tex)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","article-title":"Targeting the Cyclin-Dependent Kinases (CDK) 4\/6 in Estrogen Receptor-Positive Breast Cancers","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11912-020-00917-8","article-title":"Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4\/6 Inhibitor","volume":"22","author":"Xi","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early Adaptation and Acquired Resistance to CDK4\/6 Inhibition in Estrogen Receptor-Positive Breast Cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.379","article-title":"Acquired CDK6 Amplification Promotes Breast Cancer Resistance to CDK4\/6 Inhibitors and Loss of ER Signaling and Dependence","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.154","article-title":"Therapeutic CDK4\/6 Inhibition in Breast Cancer: Key Mechanisms of Response and Failure","volume":"29","author":"Dean","year":"2010","journal-title":"Oncogene"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12010","article-title":"A Gene Expression Signature of Retinoblastoma Loss-of-Function is a Predictive Biomarker of Resistance to Palbociclib in Breast Cancer Cell Lines and is Prognostic in Patients with ER Positive Early Breast Cancer","volume":"7","author":"Malorni","year":"2016","journal-title":"Oncotarget"},{"key":"B19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ccell.2017.11.006","article-title":"Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib","volume":"32","author":"Gong","year":"2017","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 Mutations and Acquired Resistance to CDK 4\/6 Inhibitors in Patients With Metastatic Breast Cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-0264","article-title":"The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial","volume":"8","author":"O\u2019Leary","year":"2018","journal-title":"Cancer Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20160152","article-title":"APC\/C and Retinoblastoma Interaction: Cross-Talk of Retinoblastoma Protein With the Ubiquitin Proteasome Pathway","volume":"36","author":"Ramanujan","year":"2016","journal-title":"Biosci Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5906","DOI":"10.1038\/ncomms6906","article-title":"Rb and FZR1\/Cdh1 Determine CDK4\/6-Cyclin D Requirement in C. elegans and Human Cancer Cells","volume":"6","author":"The","year":"2015","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive Molecular Portraits of Human Breast Tumours","volume":"490","author":"Koboldt","year":"2012","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in Patients With Cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1284-6","article-title":"Tumour Kinome Re-Wiring Governs Resistance to Palbociclib in Oestrogen Receptor Positive Breast Cancers, Highlighting New Therapeutic Modalities","volume":"39","author":"Pancholi","year":"2020","journal-title":"Oncogene"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A Landscape of Driver Mutations in Melanoma","volume":"2","author":"Eran","year":"2012","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos114","article-title":"p16-Cdk4-Rb Axis Controls Sensitivity to a Cyclin-Dependent Kinase Inhibitor PD0332991 in Glioblastoma Xenograft Cells","volume":"7","author":"Ling","year":"2012","journal-title":"Neuro-oncology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-14-2955","article-title":"CDK4 Amplification Reduces Sensitivity to CDK4\/6 Inhibition in Fusion-Positive Rhabdomyosarcoma","volume":"21","author":"Olanich","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.04.001","article-title":"EGFR L861Q and CDK4 Amplification Responding to Afatinib Combined With Palbociclib Treatment in a Patient With Advanced Lung Squamous Cell Carcinoma","author":"Jiang","year":"2020","journal-title":"Lung Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.01206-14","article-title":"Brk\/Protein Tyrosine Kinase 6 Phosphorylates p27KIP1, Regulating the Activity of Cyclin D-Cyclin-Dependent Kinase 4","volume":"35","author":"Patel","year":"2015","journal-title":"Mol Cell Biol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ccell.2016.07.003","article-title":"A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis","volume":"30","author":"Kollmann","year":"2016","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0661-5","article-title":"Targeting the Cyclin-Dependent Kinases (CDK) 4\/6 in Estrogen Receptor-Positive Breast Cancers","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res BCR"},{"key":"B34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.drup.2018.01.002","article-title":"Redundant Angiogenic Signaling and Tumor Drug Resistance","volume":"36","author":"Gacche","year":"2018","journal-title":"Drug Resist Update"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32020","article-title":"Molecular Mechanisms of Resistance to CDK4\/6 Inhibitors in Breast Cancer: A Review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00217-4","article-title":"Cell Cycle Progression Without Cyclin E\/CDK2: Breaking Down the Walls of Dogma","volume":"4","author":"GA","year":"2003","journal-title":"Cancer Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-11-0963","article-title":"Cyclin E2 Overexpression is Associated With Endocrine Resistance But Not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells","volume":"11","author":"Caldon","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2013.04.003","article-title":"A Cdk7-Cdk4 T-Loop Phosphorylation Cascade Promotes G1 Progression","volume":"50","author":"Schachter","year":"2013","journal-title":"Mol Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.063","article-title":"CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer","volume":"163","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn421213-20200709-00496","article-title":"Yangshune Correlation Analysis of Cyclin D1, Aurora Kinase-A, Fibroblast Growth Factor Receptor2 Gene Single Nucleotide Polymorphism With Pathological Indicators and Prognosis of Breast Cancer","volume":"7","author":"Zhenghui","year":"2020","journal-title":"Chin J Exp Surgery|Chin J Exp Surg"},{"key":"B41","doi-asserted-by":"publisher","first-page":"molcanther.0537.2017","DOI":"10.1158\/1535-7163.MCT-17-0537","article-title":"Combined Inhibition of mTOR and CDK4\/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-Positive Breast Cancer","volume":"17","author":"Michaloglou","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-3206","article-title":"NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4\/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"BSR20190384","DOI":"10.1042\/bsr20190384","article-title":"Inhibition of Breast Cancer Cells by Targeting E2F-1 Gene and Expressing IL15 Oncolytic Adenovirus","volume":"39","author":"Yan","year":"2019","journal-title":"Biosci Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8514","article-title":"Expression Patterns of E2F Transcription Factors and Their Potential Prognostic Roles in Breast Cancer","volume":"15","author":"Li","year":"2018","journal-title":"Oncol Lett"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2019.1644913","article-title":"Ara-c Induces Cell Cycle G1\/S Arrest by Inducing Upregulation of the INK4 Family Gene or Directly Inhibiting the Formation of the Cell Cycle-Dependent Complex CDK4\/Cyclin D1","volume":"18","author":"Sun","year":"2019","journal-title":"Cell Cycle"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-0070","article-title":"Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4\/6 Inhibitors in Targeted Therapy","volume":"23","author":"Kong","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0223084","DOI":"10.1371\/journal.pone.0223084","article-title":"P16 Methylation Increases the Sensitivity of Cancer Cells to the CDK4\/6 Inhibitor Palbociclib","volume":"14","author":"Li","year":"2019","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.14.6289","article-title":"Growth Suppression by p16ink4 Requires Functional Retinoblastoma Protein","volume":"92","author":"Medema","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/path.4896","article-title":"Palbociclib has Antitumour Effects on Pten-Deficient Endometrial Neoplasias","volume":"242","author":"Dosil","year":"2017","journal-title":"J Pathol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","article-title":"PTEN Loss Mediates Clinical Cross-Resistance to CDK4\/6 and PI3K\u03b1 Inhibitors in Breast Cancer","volume":"10","author":"Wang","year":"2020","journal-title":"Cancer Discov"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nature13948","article-title":"Convergent Loss of PTEN Leads to Clinical Resistance to a PI(3)K\u03b1 Inhibitor","volume":"518","author":"Juric","year":"2015","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0047-1","article-title":"Alterations in PTEN and ESR1 Promote Clinical Resistance to Alpelisib Plus Aromatase Inhibitors","volume":"1","author":"Razavi","year":"2020","journal-title":"Nat Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-09-0537","article-title":"Cyclin-Dependent Kinase 4-Mediated Phosphorylation Inhibits Smad3 Activity in Cyclin D-overexpressing breast cancer cells","volume":"8","author":"Zelivianski","year":"2010","journal-title":"Mol Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206791","article-title":"Differential Regulation of TGF-Beta Signaling Through Smad2, Smad3 and Smad4","volume":"22","author":"Kretschmer","year":"2003","journal-title":"Oncogene"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.05.002","article-title":"Targeting Invadopodia for Blocking Breast Cancer Metastasis","volume":"39","author":"Meirson","year":"2018","journal-title":"Drug Resist Updat"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.165","article-title":"Danielpour D Rb\/E2F4 and Smad2\/3 link Survivin to TGF-Beta-Induced Apoptosis and Tumor Progression","volume":"27","author":"Yang","year":"2008","journal-title":"Oncogene"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3758","article-title":"Molecular Mechanisms of Epithelial\u2013Mesenchymal Transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2017.1338988","article-title":"Inhibition of CDK-Mediated Smad3 Phosphorylation Reduces the Pin1-Smad3 Interaction and Aggressiveness of trIple Negative Breast Cancer Cells","volume":"16","author":"Thomas","year":"2017","journal-title":"Cell Cycle"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2270","article-title":"CDK4\/6 Inhibitors Have Potent Activity in combination With Pathway Selective Therapeutic Agents in Models of Pancreatic Cancer","volume":"5","author":"Franco","year":"2014","journal-title":"Oncotarget"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0562","article-title":"Cdk4\/6 Inhibition Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells","volume":"10","author":"Liu","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0520","article-title":"Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer","volume":"23","author":"Geenen","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445","article-title":"Resistance to Palbociclib Depends on Multiple Targetable Mechanisms Highlighting the Potential of Drug Holidays and Drug Switching To Improve Therapeutic Outcome, Abstracts: 2016 San Antonio Breast Cancer Symposium","volume":"77","author":"Martin","year":"2017","journal-title":"Cancer Res Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12935-020-01337-1","article-title":"Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model","volume":"20","author":"Grolmusz","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18147","article-title":"Estrogen-Activated MDM2 Disrupts Mammary Tissue Architecture Through a p53-Independent Pathway","volume":"8","author":"Kundu","year":"2017","journal-title":"Oncotarget"},{"key":"B66","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13045-017-0482-3","article-title":"Combined Targeting of MDM2 and CDK4 is Synergistic in Dedifferentiated Liposarcomas","volume":"10","author":"Laroche-Clary","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13058-020-01318-2","article-title":"MDM2 Inhibition in Combination With Endocrine Therapy and CDK4\/6 Inhibition For the Treatment of ER-Positive Breast Cancer","volume":"22","author":"Portman","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-17-0537","article-title":"Combined Inhibition of mTOR and CDK4\/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer","volume":"17","author":"Michaloglou","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.02.037","article-title":"PI3K-AKT-mTOR Inhibitors in Breast Cancers: From Tumor Cell Signaling to Clinical Trials","author":"Dey","year":"2017","journal-title":"Pharmacol Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27539","article-title":"Combined Inhibition of PIM and CDK4\/6 Suppresses Both mTOR Signaling and Rb Phosphorylation and Potentiates PI3K Inhibition in Cancer Cells","volume":"11","author":"Litchfield","year":"2020","journal-title":"Oncotarget"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00666","article-title":"Mechanisms of Resistance to CDK4\/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice","volume":"9","author":"McCartney","year":"2019","journal-title":"Front Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00349","article-title":"Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4\/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications","volume":"15","author":"Occhipinti","year":"2020","journal-title":"Front Genet"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2653","article-title":"Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4\/6 Inhibition in ER-Positive Breast Cancer","volume":"77","author":"Jansen","year":"2017","journal-title":"Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.05.020","article-title":"CDK 4\/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors","volume":"26","author":"Vora","year":"2014","journal-title":"Cancer Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204383","article-title":"AP-1 in Cell Proliferation and Survival","volume":"20","author":"Shaulian","year":"2001","journal-title":"Oncogene"},{"key":"B76","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/1940-6207.Capr-08-0034","article-title":"Targeting the Activator Protein 1 Transcription Factor for the Prevention of Estrogen Receptor-Negative Mammary Tumors","volume":"1","author":"Shen","year":"2008","journal-title":"Cancer Prev Res (Phila)"},{"key":"B77","doi-asserted-by":"publisher","first-page":"P4","DOI":"10.1158\/1538-7445.SABCS17-P4-03-05","article-title":"AP-1 as a Potential Mediator of Resistance to the Cyclin-Dependent Kinase (CDK) 4\/6-Inhibitor Palbociclib in ER-Positive Endocrine-Resistant Breast Cancer","volume":"78","author":"Angelis","year":"2018","journal-title":"Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1021\/jm5004733","article-title":"Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1)","volume":"16","author":"Ye","year":"2014","journal-title":"J Med Chem"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062011","article-title":"The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments","volume":"21","author":"Sobhani","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2017.10.014","article-title":"Targeting FGFR Pathway in Breast Cancer","volume":"37","author":"Perez-Garcia","year":"2018","journal-title":"Breast"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.2174\/1568009618666171214114706","article-title":"Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis","volume":"18","author":"Sahores","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","article-title":"Aberrant FGFR Signaling Mediates Resistance to CDK4\/6 Inhibitors in ER+ Breast Cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nat Commun"},{"key":"B83","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12943-016-0579-2","article-title":"EMT And Stemness: Flexible Processes Tuned by Alternative Splicing in Development and Cancer Progression","volume":"16","author":"Pradella","year":"2017","journal-title":"Mol Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7010001","article-title":"Epithelial Mesenchymal Transition in Embryonic Development, Tissue Repair and Cancer: A Comprehensive Overview","volume":"1","author":"Kim","year":"2017","journal-title":"J Clin Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/molecules21070965","article-title":"Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer","volume":"21","author":"Du","year":"2016","journal-title":"Molecules"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-417","article-title":"Cyclin D1, Id1 and EMT in Breast Cancer","volume":"11","author":"Tobin","year":"2011","journal-title":"BMC Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.4161\/15384101.2014.985071","article-title":"Reinforcing Targeted Therapeutics With Phenotypic Stability Factors","volume":"13","author":"Yaswen","year":"2014","journal-title":"Cell Cycle"},{"key":"B88","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11912-014-0426-9","article-title":"Immunotherapy for the Treatment of Breast Cancer","volume":"2","author":"Ernst","year":"2015","journal-title":"Curr Oncol Rep"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2017.07.002","article-title":"Immunotherapy For Triple-Negative Breast Cancer: Existing Challenges and Exciting Prospects","volume":"32","author":"Jia","year":"2017","journal-title":"Drug Resist Update"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 Inhibition Triggers Anti-Tumour Immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"},{"key":"B92","doi-asserted-by":"publisher","first-page":"10.3390\/ijms20040857","DOI":"10.3390\/ijms20040857","article-title":"Endoplasmic Reticulum Stress and Unfolded Protein Response in Breast Cancer: The Balance Between Apoptosis and Autophagy and Its Role in Drug Resistance","volume":"20","author":"Sisinni","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1617","article-title":"The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.4161\/15548627.2014.981788","article-title":"Inhibition of Autophagy as a New Means of Improving Chemotherapy Efficiency in High-LC3B Triple-Negative Breast Cancers","volume":"10","author":"Lefort","year":"2014","journal-title":"Autophagy"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.115865","article-title":"Kimchi A Life in the Balance - A Mechanistic View of the Crosstalk Between Autophagy and Apoptosis","volume":"125","author":"Rubinstein","year":"2012","journal-title":"J Cell Sci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.2174\/092986709788186147","article-title":"Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance","volume":"16","author":"Gangemi","year":"2009","journal-title":"Curr Med Chem"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0097","article-title":"Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive\/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)","volume":"21","author":"Verma","year":"2016","journal-title":"Oncologist"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-0754","article-title":"MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)\/HER2(-) Metastatic Breast Cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated Results from MONALEESA-2, a Phase III Trial of First-Line Ribociclib Plus Letrozole Versus Placebo Plus Letrozole in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30292-4","article-title":"Ribociclib Plus Endocrine Therapy for Premenopausal Women With Hormone-Receptor-Positive, Advanced Breast Cancer (MONALEESA-7): A Randomised Phase 3 Trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.78.9909","article-title":"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.651541\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T06:53:26Z","timestamp":1622012006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.651541\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":103,"alternative-id":["10.3389\/fonc.2021.651541"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.651541","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"article-number":"651541"}}